Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.

Publication Type:

Journal Article


Current hematologic malignancy reports, Volume 8, Issue 2, p.132-40 (2013)


2013, Clinical Research Division, June 2013


The incidence of acute myeloid leukemia (AML) is expected to increase in conjunction with our ageing population. Although it is proving to be a heterogeneous disease process, the only treatment with proven survival benefit for poor risk AML remains allogeneic hematopoietic cell transplant. Although this is presumed to be a curative strategy, many patients relapse after transplant, prompting us to examine various ways that we can improve outcomes. These efforts involve every step of AML diagnostics and therapy, including the intricate processes of conditioning, graft manipulation and immunomodulation. The hope is that improvement in these steps will ultimately improve survival and decrease relapse rates for AML patients after transplant.